Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolized and is cleared by the kidneys via OAT1, which is not affected by glecaprevir/pibrentasvir.

Coadministration has not been studied and thyroid metabolism is complicated. The major pathway is sequential deiodination (but there are few published data on the enzymes involved) and conjugation with glucuronides and sulphates also occurs. A few individual case reports indicate some potential CYP involvement but this is unlikely to be clinically significant. Data suggest that endogenous T3 and T4 may be transported by OATP1B1 but no data that they cause inhibition. In the absence of further data consider monitoring thyroid levels.

Coadministration of losartan and glecaprevir/pibrentasvir increased losartan Cmax and AUC by 151% and 56%. Cmax of the losartan active carboxylic metabolite was increased by 118% , but there was no change in AUC (14% increase). These effects were not deemed clinically significant and no dose adjustment is required when glecaprevir/pibrentasvir is coadministered with losartan.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thiamine is predominantly eliminated unchanged by the kidneys.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isosorbide mononitrate is completely absorbed and is not subject to first pass metabolism by the liver. It is excreted mainly in the urine. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isosorbide mononitrate is completely absorbed and is not subject to first pass metabolism by the liver. It is excreted mainly in the urine.